YKL-40 is elevated in morbidly obese patients and declines after weight loss

Obesity Surgery

Volumn 19, Issue 11, 2009, Pages 1557-1563

  Hempen, Moritz ^a   Kopp, Hans Peter ^b   Elhenicky, Marie ^a   Höbaus, Clemens ^a   Brix, Johanna Maria ^b   Koppensteiner, Renate ^a   Schernthaner, Guntram ^b   Schernthaner, Gerit Holger ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Diabetes mellitus; Human; Insulin resistance; Monocyte chemoattractant protein 1; Morbid obesity; Type 2; YKL 40

Indexed keywords

BIOLOGICAL MARKER; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BARIATRIC SURGERY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LINEAR REGRESSION ANALYSIS; MALE; MORBID OBESITY; MORTALITY; OBESITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; BARIATRIC SURGERY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LECTINS; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; OBESITY, MORBID; POSTOPERATIVE PERIOD; WEIGHT LOSS;

EID: 70449523003     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-009-9917-4     Document Type: Article

References (35)

1. J Stevens J Cai ER Pamuk, et al. 1998 The effect of age on the association between body-mass index and mortality N Engl J Med 338 1 7 10.1056/NEJM199801013380101 1:STN:280:DyaK1c%2FmvF2gug%3D%3D 9414324 (Pubitemid 28040168)
2. KR Fontaine DT Redden C Wang, et al. 2003 Years of life lost due to obesity JAMA 289 2 187 193 10.1001/jama.289.2.187 12517229 (Pubitemid 36068706)
3. S Yusuf S Hawken S Ounpuu, et al. 2005 Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study Lancet 366 1640 1649 10.1016/S0140-6736(05)67663-5 16271645 (Pubitemid 41552419)
4. S Yusuf M Vaz P Pais 2004 Tackling the challenge of cardiovascular disease burden in developing countries Am Heart J 148 1 4 10.1016/j.ahj.2004.03. 045 15215784 (Pubitemid 38900473)
5. L Sjöström K Narbro CD Sjöström, et al. 2007 Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 357 741 752 10.1056/NEJMoa066254 17715408
6. HP Kopp CW Kopp A Festa, et al. 2003 Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients Arterioscler Thromb Vasc Biol 23 1042 1047 10.1161/01.ATV.0000073313.16135.21 1:CAS:528:DC%2BD3sXktlantrw%3D 12714437 (Pubitemid 36713558)
7. HP Kopp K Krzyzanowska M Möhlig, et al. 2005 Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women Int J Obes (Lond) 29 766 771 10.1038/sj.ijo.0802983 1:CAS:528:DC%2BD2MXkvV2ntrY%3D (Pubitemid 40897012)
8. K Matsushima CG Larsen GC DuBois, et al. 1989 Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line J Exp Med 169 1485 1490 10.1084/jem.169.4. 1485 1:CAS:528:DyaL1MXhvFSrs78%3D 2926331 (Pubitemid 19104979)
9. CC Gerhardt IA Romero R Cancello, et al. 2001 Chemokines control fat accumulation and leptin secretion by cultured human adipocytes Mol Cell Endocrinol 175 81 92 10.1016/S0303-7207(01)00394-X 1:CAS:528: DC%2BD3MXivFeitr8%3D 11325518 (Pubitemid 32372545)
10. G Schernthaner JM Morton 2008 Bariatric surgery in patients with morbid obesity and type 2 diabetes Diabetes Care 31 Suppl 2 S297 S302 10.2337/dc08-s270 18227500
11. H Buchwald Y Avidor E Braunwald, et al. 2004 Bariatric surgery: a systematic review and meta-analysis JAMA 292 1724 1737 10.1001/jama.292.14.1724 1:CAS:528:DC%2BD2cXos1OjtLg%3D 15479938 (Pubitemid 39346675)
12. R Stamler J Stamler WF Riedlinger, et al. 1978 Weight and blood pressure. Findings in hypertension screening of 1 million Americans JAMA 240 1607 1610 10.1001/jama.240.15.1607 1:STN:280:DyaE1M%2FgslKqsA%3D%3D 691146 (Pubitemid 9047223)
13. P Poirier TD Giles GA Bray, et al. 2006 Obesity and cardiovascular disease. Pathophysiology, evaluation, and effect of weight loss Arterioscler Thromb Vasc Biol 26 968 976 10.1161/01.ATV.0000216787.85457.f3 1:CAS:528:DC%2BD28XjsVersb4%3D 16627822 (Pubitemid 43732100)
14. JA de Lemos DA Morrow MS Sabatine, et al. 2003 Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes Circulation 107 690 695 10.1161/01.CIR.0000049742.68848.99 12578870 (Pubitemid 36222595)
15. I Dahlman M Kaaman T Olsson, et al. 2005 A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects J Clin Endocrinol Metab 90 5834 5840 10.1210/jc.2005-0369 1:CAS:528: DC%2BD2MXhtFWjt7jL 16091493 (Pubitemid 41415500)
16. S Ylä-Herttuala BA Lipton ME Rosenfeld, et al. 1991 Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions Proc Natl Acad Sci U S A 88 5252 5256 10.1073/pnas.88.12.5252 2052604
17. M Takeya T Yoshimura EJ Leonard, et al. 1993 Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody Hum Pathol 24 534 539 10.1016/0046-8177(93)90166-E 1:STN:280:DyaK3s3lvFKgsw%3D%3D 7684023 (Pubitemid 23145806)
18. S Inoue K Egashira W Ni, et al. 2002 Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice Circulation 106 2700 2706 10.1161/01.CIR.0000038140.80105.AD 1:CAS:528:DC%2BD38XosFCrsr4%3D 12438296 (Pubitemid 35364925)
19. GH Schernthaner HP Kopp S Kriwanek, et al. 2006 Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity Obes Surg 16 709 715 10.1381/096089206777346763 16756729 (Pubitemid 43874824)
20. JS Johansen N Milman M Hansen, et al. 2005 Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity? Respir Med 99 396 402 10.1016/j.rmed.2004.09.016 15763444 (Pubitemid 40347821)
21. JS Johansen P Christoffersen S Møller, et al. 2000 Serum YKL-40 is increased in patients with hepatic fibrosis J Hepatol 32 911 920 10.1016/S0168-8278(00)80095-1 1:CAS:528:DC%2BD3cXks1Sjtrs%3D 10898311 (Pubitemid 30368084)
22. T Matsumoto T Tsurumoto 2001 Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters Clin Exp Rheumatol 19 655 660 1:STN:280:DC%2BD38%2Fmslaqtw%3D%3D 11791636
23. J Dupont MK Tanwar HT Thaler, et al. 2004 Early detection and prognosis of ovarian cancer using serum YKL-40 J Clin Oncol 22 3330 3339 10.1200/JCO.2004.09.112 1:CAS:528:DC%2BD2cXpsVGrsbs%3D 15310777 (Pubitemid 41103690)
24. JS Johansen L Drivsholm PA Price, et al. 2004 High serum YKL-40 level in patients with small cell lung cancer is related to early death Lung Cancer 46 333 340 10.1016/j.lungcan.2004.05.010 15541818 (Pubitemid 39487308)
25. CN Rathcke JS Johansen H Vestergaard 2006 YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance Inflamm Res 55 53 59 10.1007/s00011-005-0010-8 1:CAS:528:DC%2BD28Xis1Cktrs%3D 16612564
26. AR Nielsen C Erikstrup JS Johansen, et al. 2008 Plasma YKL-40: a BMI-independent marker of type 2 diabetes Diabetes 57 3078 3082 10.2337/db08-0182 1:CAS:528:DC%2BD1MXhsleis70%3D 18650368
27. RG Boot TA van Achterberg BE van Aken, et al. 1999 Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages Arterioscler Thromb Vasc Biol 19 687 694 1:CAS:528:DyaK1MXitFGnsb0%3D 10073974
28. EM Fach LA Garulacan J Gao, et al. 2004 In vitro biomarker discovery for atherosclerosis by proteomics Mol Cell Proteomics 3 1200 1210 10.1074/mcp.M400160-MCP200 1:CAS:528:DC%2BD2MXhvFarug%3D%3D 15496433
29. M Kucur FK Isman B Karadag, et al. 2007 Serum YKL-40 levels in patients with coronary artery disease Coron Artery Dis 18 391 396 10.1097/MCA. 0b013e328241d991 17627189 (Pubitemid 47186840)
30. J Kastrup JS Johansen P Winkel CLARICOR Trial Group, et al. 2009 High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease Eur Heart J 30 1066 1072 10.1093/eurheartj/ehp049 1:CAS:528:DC%2BD1MXlsVChu70%3D 19270316
31. C Nøjgaard NB Høst IJ Christensen, et al. 2008 Serum levels of YKL-40 increases in patients with acute myocardial infarction Coron Artery Dis 19 257 263 10.1097/MCA.0b013e3282f40dd5 18480670
32. AC Wittgrove GW Clark LJ Tremblay 1994 Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases Obes Surg 4 353 357 10.1381/096089294765558331 10742801 (Pubitemid 24371404)
33. DR Matthews JP Hosker AS Rudenski, et al. 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412 419 10.1007/BF00280883 1:CAS:528:DyaL2MXlslKnu7k%3D 3899825 (Pubitemid 15018832)
34. KC Nishikawa AJ Millis 2003 gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells Exp Cell Res 287 79 87 10.1016/S0014- 4827(03)00069-7 1:CAS:528:DC%2BD3sXksVyrtbs%3D 12799184 (Pubitemid 36683203)
35. P Libby PM Ridker A Maseri 2002 Inflammation and atherosclerosis Circulation 105 1135 1143 10.1161/hc0902.104353 1:CAS:528:DC%2BD38XislWhu7k%3D 11877368 (Pubitemid 34212626)